Ubs Asset Management Americas Inc I Mab Transaction History

Ubs Asset Management Americas Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$8.27 - $18.43 $2.11 Million - $4.7 Million	254,876 Added 125.04%	458,706 $5.18 Million
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $87,717 - $328,275	-6,995 Reduced 3.32%	203,830 $3.31 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $4.12 Million - $6.78 Million	91,021 Added 75.97%	210,825 $9.99 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $736,249 - $1.09 Million	12,876 Added 12.04%	119,804 $8.68 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $5.12 Million - $8.98 Million	106,928 New	106,928 $8.98 Million

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.